Lupin declines after poor Q4 results

Lupin lost 3.49% to Rs 1,688.25 at 15:21 IST on BSE after consolidated net profit fell 1.08% to Rs 547 crore on 0.08% growth in net sales to Rs 3054 crore in Q4 March 2015 over Q4 March 2014.

The Q4 result was announced during market hours today, 13 May 2015.

Meanwhile, the S&P BSE Sensex was up 366.38 points or 1.36% at 27,243.86.

On BSE, so far 3.35 lakh shares were traded in the counter as against average daily volume of 82.771 shares in the past one quarter.

The stock was volatile. The stock fell as much as 3.89% at the day's low of Rs 1,681.05 so far during the day. The stock rose as much as 3.07% at the day's high of Rs 1,803 so far during the day. The stock had hit a record high of Rs 2,112 on 8 April 2015. The stock had hit a 52-week low of Rs 903.95 on 27 May 2014.

The stock had underperformed the market over the past one month till 12 May 2015, sliding 10.96% compared with Sensex's 6.93% fall. The scrip had, however, outperformed the market in past one quarter, surging 7.99% as against Sensex's 6.69% fall.

The large-cap company has equity capital of Rs 89.96 crore. Face value per share is Rs 2.

Lupin's EBITDA (earnings before interest, taxation, depreciation, and amoritzation) declined 8.57% to Rs 806.50 crore in Q4 March 2015 over Q4 March 2014.

Commenting on the company's financial performance, Managing Director of Lupin Mr. Nilesh Gupta said that higher price erosion in the US as well as a slowdown in product approvals impacted growth in the quarter, but overall the company has done well to improve gross margins and enhance profitability for the year. Lupin continues to ramp up investment in research in segments like inhalation, complex injectables and biosimilars, Gupta said. Lupin's execution strength, pipeline evolution and planned M&A will drive the company's future as a global generic and specialty pharmaceutical company, Gupta added.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs.

Powered by Capital Market - Live News